Arcturus Therapeutics Holdings (ARCT) Equity Average (2018 - 2026)

Arcturus Therapeutics Holdings has reported Equity Average for 9 years, with the latest figure at $202.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 14.62% year-over-year to $202.7 million; the trailing twelve-month figure through Mar 2026 stood at $202.7 million (down 14.62% YoY), and the FY2025 full-year result was $227.5 million, down 12.42% from the prior year.
• Equity Average for Q1 2026 stood at $202.7 million, down from $219.3 million in the prior quarter.
• The five-year high for Equity Average was $307.2 million in Q2 2023, with the low at $158.2 million in Q3 2022.
• Historically, Equity Average has averaged $240.2 million across 5 years, with a median of $237.4 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average sank 46.0% — and 2023, when it jumped 78.66%.
• Arcturus Therapeutics Holdings' Equity Average stood at $208.0 million in 2022, then jumped by 34.28% to $279.3 million in 2023, then dropped by 9.98% to $251.4 million in 2024, then retreated by 12.79% to $219.3 million in 2025, then fell by 7.57% to $202.7 million in 2026.
• The last three Equity Average figures came in at $202.7 million (Q1 2026), $219.3 million (Q4 2025), and $227.8 million (Q3 2025), per Business Quant data.